# **Problem**

Pharma and biotech urgently need platforms that deliver rapid, safe, effective and easily customizable immunological formulations. Legacy vaccine and biologics technologies are slow to iterate and costly to scale, while newer platforms face regulatory and public scrutiny that delays deployment. The combined effect is delayed response to emerging pathogens, low scalability, higher development costs, limited personalization, and restricted ability to rapidly update formulations to match evolving threats.



#### **Our Solution**

Our modular, self-assembling platform enables Lego-like next-generation immunoengineering that is rapid and versatile. Standardized, stable building blocks reduce formulation complexity and manufacturing variability while enabling combinatorial design to tackle complex targets. The platform supports personalized and updatable solutions, demonstrated by a Parkinson's disease immunotherapy program and an updatable multi-pathogen respiratory vaccine.





**Damiin** Álvarez-Paggi Co-founder



Salvador Ventura **Polack** Co-founder



Scientific & Business Advisor




**Daniel** Murgida Co-founder



Ariel **Notcovich Business** Advisor

# EULTEKA NANOBIOENGINEERING

#### **MISSION & VISION**




### **MULTIBILLION DOLLAR TAM**

#### **46**% • Immunotherapeutics

45% • Vaccines

6% • Nanotech-Based Devices

3% • Drug design & Development



### **REVENUE & ROI POTENTIAL**

We aim at revolutionizing global health through nextgeneration

immunoengineering

 $\mathbf{\Phi}$ **Protein library** generation Stable building blocks

Self-assembly Subunit selection for combinatorial design


**Next-Gen Nanobiodevices** Fast, modular, cost-effective production

2023

**NBMods** 

platform PoC

Our NBMods platform & business model facilitate the (co)creation of a robust product portfolio leveraging on a streamlined design and production pipeline enabling incremental modifications & combinatorial design.



## **B2B & B2B2C BUSINESS MODEL**

Our B2B and B2B2C business model involves partnering with Pharma companies with GMP capabilities, enabling multiple revenue streams

Product (co)development

Licensing



**Royalties** 


#### **ROADMAP**


#### Seeking 500K to reach key milestones to prepare for our Seed round













**Updatable Respiratory** disease Vaccine Partnering & Licensing





Parkinson **Immunotherapy** 



**PCT Patents Strategic Partnerships** IND Ready: Parkinson Disease Immunotherapy

IND Ready: Updatable Influenza Vaccine

**Partners** 











**Provisional Patents** Immunotherapy PoC



